New Delhi Hyderabad-based drug maker Bharat Biotech has got regulatory approval to conduct phase-3 clinical trials of its intranasal COVID-19 vaccine as a booster dose, says Dr Sanjay Rai, Senior Epidemiologist at All India Institute of Medical Sciences (AIIMS) in Delhi. , said on Sunday Vaccination Could be a game-changer in the fight against the pandemic if it provides mucosal immunity.
“If this vaccine provides mucosal immunity, it will be a great achievement for mankind. There are 33 vaccines worldwide but none are effective in preventing infection. We are hoping that this vaccine will provide mucosal immunity.” who can stop it Ahead Infection,” Dr Rai told ANI here.
As the budget session begins from Monday, AIIMS senior epidemiologist expects the need of the hour to strengthen public Health system at all primary, secondary level and tertiary levels.
“This is not the last pandemic, we must be prepared for future pandemics and to deal with it, we need to strengthen the public health system,” he said.
The Drugs Controller General of India (DCGI) has given permission to Hyderabad-based biotechnology firm Bharat Biotech, manufacturer of India’s first indigenous COVID-19 vaccine Covaxin, for intranasal booster dose trials. The trial will be conducted at nine different places.
Earlier this month, DCGI’s Subject Expert Committee (SEC) had given in-principle approval to Bharat Biotech to conduct a ‘Phase III Efficacy Study and Phase III Booster Dose Study’ for its intranasal COVID vaccine BBV154.
This story has been published without modification in text from a wire agency feed. Only the title has been changed.
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,